The impact of a medical food containing gammalinolenic and eicosapentaenoic acids on asthma management and the quality of life of adult asthma patients

References

• Smith MJ, Ford-Hutchinson AW, Bray MA. Leukotriene B: a potential mediator of inflammation. J Pharm Pharmacol 1980;32:517–18
   PubMed Web of Science ®Google Scholar
• Piper PJ, Samhoun MN, Tippins JR, et al. Slow-reacting substances and their formation by a lipoxygenase pathway. Agents Actions 1980;10:541–7
   PubMedGoogle Scholar
• Goetzl EJ. Leukocyte recognition and metabolism of leukotrienes. Fed Proc 1983;42:3128–31
   PubMedGoogle Scholar
• Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339:147–52
   PubMed Web of Science ®Google Scholar
• Kane GC, Pollice M, Kim CJ, et al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 1996;97:646–54
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Trudeau JB, Kaminsky DA, et al. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995;152:897–905
   PubMed Web of Science ®Google Scholar
• Capra V, Ambrosio M, Riccioni G, Rovati GE. Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. Curr Med Chem 2006;13:3213–26
   PubMed Web of Science ®Google Scholar
• Back M, Hansson GK. Leukotriene receptors in atherosclerosis. Ann Med 2006;38:493–502
   PubMed Web of Science ®Google Scholar
• Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 2007;67: 887–901
   PubMed Web of Science ®Google Scholar
• Poff CD, Balazy M. Drugs that target lipoxygenases and leukotrienes as emerging therapies for asthma and cancer. Curr Drug Targets Inflamm Allergy 2004;3:19–33
   PubMedGoogle Scholar
• Leonardi S, Marchese G, Marseglia GL, La Rosa M. Montelukast in allergic diseases beyond asthma. Allergy Asthma Proc. 2007;28:287–91
   PubMedGoogle Scholar
• Chilton-Lopez T, Surette ME, Swan DD, et al. Metabolism of gammalinolenic acid in human neutrophils. J Immunol 1996;156:2941–7
   Google Scholar
• Chapkin RS, Miller CC, Somers SD, Erickson KL. Utilization of dihomo-gamma-linolenic acid (8,11,14-eicosatrienoic acid) by murine peritoneal macrophages. Biochim Biophys Acta 1988;959:322–31
   PubMed Web of Science ®Google Scholar
• Johnson MM, Swan DD, Surette ME, et al. Dietary supplementation with gamma-linolenic acid alters fatty acid content and eicosanoid production in healthy humans. J Nutr 1997;127:1435–44
   PubMed Web of Science ®Google Scholar
• Pullman-Mooar S, Laposata M, Lem D, et al. Alteration of the cellular fatty acid profile and the production of eicosanoids in human monocytes by gamma-linolenic acid. Arthritis Rheum 1990;33:1526–33
   Google Scholar
• Ziboh VA, Fletcher MP. Dose-response effects of dietary gammalinolenic acid-enriched oils on human polymorphonuclearneutrophil biosynthesis of leukotriene B4. Am J Clin Nutr 1992;55:39–45
   PubMed Web of Science ®Google Scholar
• Barham JB, Edens MB, Fonteh AN, et al. Addition of eicosapentaenoic acid to gamma-linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. J Nutr 2000;130:1925–31
   PubMed Web of Science ®Google Scholar
• Surette ME, Koumenis IL, Edens MB, et al. Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects. Clin Ther 2003;25:948–71
   PubMed Web of Science ®Google Scholar
• Surette ME, Koumenis IL, Edens MB, et al. Inhibition of leukotriene biosynthesis by a novel dietary fatty acid formulation in patients with atopic asthma: a randomized, placebo-controlled, parallel-group, prospective trial. Clin Ther 2003;25:972–9
   PubMed Web of Science ®Google Scholar
• Pacheco Y, Hosni R, Chabannes B, et al. Leukotriene B4 level in stimulated blood neutrophils and alveolar macrophages from healthy and asthmatic subjects. Effect of beta-2 agonist therapy. Eur J Clin Invest 1992;22:732–9
   PubMed Web of Science ®Google Scholar
• Radeau T, Chavis C, Damon M, et al. Enhanced arachidonic acid metabolism and human neutrophil migration in asthma. Prostaglandins Leukot Essent Fatty Acids 1990;41:131–8
   PubMed Web of Science ®Google Scholar
• Shindo K, Koide K, Fukumura M. Enhancement of leukotriene B4 release in stimulated asthmatic neutrophils by platelet activating factor. Thorax 1997;52: 1024–9
   Google Scholar
• Cheria-Sammari S, Aloui R, Gormand F, et al. Leukotriene B4 production by blood neutrophils in allergic rhinitis – effects of cetirizine. Clin Exp Allergy 1995;25: 729–36
   Google Scholar
• Sampson AP, Thomas RU, Costello JF, Piper PJ. Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects. Br J Clin Pharmacol 1992;33:423–30
   PubMed Web of Science ®Google Scholar
• Orphan Drug Amendments of 1988. United States Public law 97–414
   Google Scholar
• Food and Drug Administration. Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. US. Department of Health and Human Services. http://www.fda.gov/CDER/ GUIDANCE/5460dft.pdf. 2006
   Google Scholar
• Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81–7
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Cox FM, et al. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999;14:32–8
   PubMed Web of Science ®Google Scholar
• Juniper EF, O’Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902–7
   PubMed Web of Science ®Google Scholar
• Pinnock H, Juniper EF, Sheikh A. Concordance between supervised and postal administration of the Mini Asthma Quality of Life Questionnaire (MiniAQLQ) and Asthma Control Questionnaire (ACQ) was very high. J Clin Epidemiol 2005;58:809–14
   Google Scholar
• Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005;99:553–8. Epub 2004, Nov 26
   Google Scholar
• Juniper EF, O’Byrne PM, Roberts JN. Measuring asthma control in group studies: do we need airway calibre and rescue beta2agonist use? Respir Med 2001;95:319–23
   PubMed Web of Science ®Google Scholar
• Moy ML, Israel E, Weiss ST, et al. Clinical predictors of health-related quality of life depend on asthma severity. Am J Resp Crit Care Med 2001;163:924–9
   PubMed Web of Science ®Google Scholar
• Ehrs PO, Nokela M, Stallberg B, et al. Brief questionnaires for patient-reported outcomes in asthma: validation and usefulness in a primary care setting. Chest 2006;129:925–32
   PubMed Web of Science ®Google Scholar
• Riccioni G, Della Vecchia R, et al. Effect of the two different leukotriene receptor antagonists, montelukast and zafirlukast, on quality of life: a 12-week randomized study. Allergy Asthma Proc 2004;25:445–8
   PubMed Web of Science ®Google Scholar
• Juniper EF, Stahl E, O’Byrne PM. Minimal important difference for the asthma control questionnaire. Am J Respir Crit Care Med 2001;163:A642
   Google Scholar
• Pinnock H, Sheikh A, Juniper EF. Evaluation of an intervention to improve successful completion of the Mini-AQLQ: comparison of postal and supervised completion. Prim Care Respir J 2004;13:36–41
   Google Scholar
• Baghi H, Atherton M. Construct validity and reliability of scores on scales to measure the impairment of health-related quality of life in persons with asthma. J Nurs Meas 2004;12:21–31
   PubMedGoogle Scholar
• Wenzel SE. The role of leukotrienes in asthma. Prostaglandins Leukot Essent Fatty Acids 2003;69:145–55
   PubMed Web of Science ®Google Scholar
• Creticos PS. Treatment options for initial maintenance therapy of persistent asthma: a review of inhaled corticosteroids and leukotriene receptor antagonists. Drugs 2003;63:1–20
   PubMedGoogle Scholar